Pharmacokinetics and safety of ascending single doses of DZ-2640, a new oral carbapenem antibiotic, administered to healthy Japanese subjects

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 3, 2000, Pages 578-582

  Tanaka, Makoto ^a   Kato, Kinuyo ^a   Hakusui, Hideo ^a   Murakami, Yoichi ^a   Sato, Kenichi ^a   Ito, Yasushi ^a   Kawamoto, Keiji ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(6,7 DIHYDRO 5H PYRROLO[1,2 A]IMIDAZOL 6 YL)THIO] 6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID; 3 [(6,7 DIHYDRO 5H PYRROLO[1,2 A]IMIDAZOL 6 YL)THIO] 6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID PIVALOYLOXYMETHYL ESTER; 3[[6,7 DIHYDRO 5H PYROLO(1,2 A)IMIDAZOL 6 YL]THIO] 6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 1 AZABICYCLO(3.2.0) HEPT 2 ENE 2 CARBOXYLIC ACID; CARBAPENEM DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG URINE LEVEL; FOOD INTAKE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN EXPERIMENT; JAPAN; KIDNEY CLEARANCE; KIDNEY TUBULE EXCRETION; MALE; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL;

BIOLOGICAL ASSAY; BLOOD PROTEINS; CARBAPENEMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; HUMANS; JAPAN; MALE; PROTEIN BINDING;

EID: 0034001142     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.3.578-582.2000     Document Type: Article

References (8)

1. Melegh, B., J. Kerner, and L. L. Bieber. 1987. Pivampicillin-promoted excretion of pivaloylcarnitine in humans. Biochem. Pharmacol. 36:3405-3499.
2. Nakashima, M., and K. Kosuge. 1996. Influence of multiple-dose administration of cefetamet pivoxil on blood and urinary concentrations of carnitine and effects of simultaneous administration of carnitine with cefetamet pivoxil. Chemotherapy (Tokyo) 49:966-979.
3. Nakashima, M., T. Uematsu, T. Oguma, T. Yoshida, K. Mizojiri, S. Matsuno, and S. Yamamoto. 1992. Phase I clinical studies of S-1108: safety and pharmacokinetics in a multiple-administration study with special emphasis on the influence on carnitine body stores. Antimicrob. Agents Chemother. 36:762-768.
4. Tanaka, M., M. Hohmura, T. Nishi, K. Sato, and I. Hayakawa. 1997. Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640. Antimicrob. Agents Chemother. 41:1260-1268.
5. Tanaka, M., and K. Kato. 1999. Sensitive semi-microcolumn high-performance liquid chromatographic method for the determination of DU-6681, the active parent drug of a new oral carbapenem antibiotic, DZ-2640, in human plasma and urine using a column-switching system as sample clean-up procedure. J. Chromatogr. B 724:73-82.
6. Totsuka, K., K. Shimizu, M. Konishi, and S. Yamamoto. 1992. Metabolism of S-1108, a new oral cephem antibiotic, and metabolic profiles of its metabolites in humans. Antimicrob. Agents Chemother. 36:757-761.
7. Transwell, P., and J. Koup. 1993. TopFit: a PC-based pharmacokinetic/ pharmacodynamic data analysis program. Int. J. Clin. Pharmacol. Ther. Toxicol. 31:514-520.
8. Umemura, K., Y. Ikeda, K. Kondo, M. Nakashima, H. Nagamura, M. Hisaoka, H. Nishino, and M. Tajima. 1997. Safety and pharmacokinetics of CS-834, a new oral carbapenem antibiotic, in healthy volunteers. Antimicrob. Agents Chemother. 41:2664-2669.